1 published article · Updated continuously
7 trials tracked for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 7 in phase 3 or 4 and 2 with published results. The most-cited published study has 75 citations.
Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical evidence for Chronic Inflammatory Demyelinating Polyradiculoneuropathy includes several pharmacological interventions with varying outcomes on disability scales and physical metrics. NewGam demonstrated improvements in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score, Grip Strength Score, and Inflammatory Rasch-built Overall Disability Scale (I-RODS Score) 2. Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified showed a significant difference in responder rates between treatment groups (54.2 vs 20.7; p<0.001) and significant improvements in Grip Strength (p<0.001), though it did not significantly change the amplitude of the most severely affected motor nerve (p=0.542) 7.
HYQVIA demonstrated a statistically significant reduction in relapse rates during Epoch 1 (31.4 vs 9.7; p=0.0045) and a significant improvement in the Rasch-built Overall Disability Scale (R-ODS) from baseline (-6.1 vs -0.9; p=0.030). However, its impact on the percentage of participants experiencing worsening functional disability did not reach statistical significance (p=0.0896) 4. Additionally, HYQVIA was associated with a 7.1% rate of treatment-emergent adverse events potentially resulting from immune-mediated responses 3.
Other interventions showed varying results: I10E demonstrated a responder rate of 32 (p<0.0001) 5, while Fingolimod showed no significant difference in time to first confirmed worsening on the adjusted INCAT scale (721.0 vs 540.0; p=0.9838) 1. IgPro20 showed no change from baseline in CIDP total adjusted INCAT scores or Medical Research Council (MRC) scores, with a 75.6% incidence of adverse events 6.
AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
